Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan 22;100(3):e24277.
doi: 10.1097/MD.0000000000024277.

Comparative efficacy and safety of traditional Chinese patent medicine for NAFLD in childhood or adolescence: A protocol for a Bayesian network meta analysis

Yuli Sun  1   2 , Zhaofeng Tan  2 , Zhenyuan Jiang  1 , Min Li  2 , Weiqin Wang  2 , Yaoyao Huang  1 , Jianguang Sun  1
Affiliations

Comparative efficacy and safety of traditional Chinese patent medicine for NAFLD in childhood or adolescence: A protocol for a Bayesian network meta analysis

Yuli Sun et al. Medicine (Baltimore). .

Abstract

Background: Nonalcoholic fatty liver disease is a common reason for chronic liver disease in children and adults. The increasing incidence of the disease has become one of the most critical public health problems in the 21st century, closely related to genetic and environmental factors. So far, apart from changing lifestyle and diet, modern medicine still lacks effective treatment measures. Chinese patent medicine has the advantages of apparent curative effect, overall regulation and fewer side effects. However, there is a lack of research on the simultaneous comparison of various Chinese patent medicines. Therefore, we used a reticular meta-analysis to indirectly compare the efficacy and safety of different oral Chinese patent medicines through standard reference.

Method: We will conduct a comprehensive and systematic search of Chinese and English databases from the beginning to December 2020. All randomized controlled trials (RCTs) of oral Chinese patent medicine for NAFLD in children will be searched. The 2 researchers then independently filter the retrieved literature, extract the data according to the data extraction table and assess the risk of bias. We will perform a pair of meta-analyses and a Bayesian network meta-analysis. STATA and Win BUGS software will be used for data analysis.

Results: This study will thoroughly compare and analyze the differences in the efficacy of all kinds of TCPM in NAFLD treatment in childhood or adolescence.

Conclusion: This study will provide reference and evidence support for clinical drug selection optimization.

Ethics and dissemination: This study does not require ethical approval.

Inplasy registration number: 2020120068.

PubMed Disclaimer

Conflict of interest statement

We declare no conflicts of interest.

References

    1. Temple J, et al. A guide to non-alcoholic fatty liver disease in childhood and adolescence. Intern J Mol Sci 2016;17:947. - PMC - PubMed
    1. Welsh JA, Karpen S, Vos MB. Increasing prevalence of nonalcoholic fatty liver disease among United States adolescents, 1988-1994 to 2007-2010. J Pediatr 2013;162: 496-500.e1. - PMC - PubMed
    1. Anderson EL, Howe LD, Jones HE, et al. The prevalence of non-alcoholic fatty liver disease in children and adolescents: a systematic review and meta-analysis. Plos One 2015;10:e140908. - PMC - PubMed
    1. Lawlor DA, et al. Nonalcoholic fatty liver disease, liver fibrosis, and cardiometabolic risk factors in adolescence: a cross-sectional study of 1874 general population adolescents. JClinEndocrinolMetab 2014;99:E410–7. - PMC - PubMed
    1. Alisi A, et al. Non-alcoholic fatty liver disease and metabolic syndrome in adolescents: pathogenetic role of genetic background and intrauterine environment. Ann Med 2012;44:29–40. - PubMed

Substances